Medigene AG Implements Share Capital Reduction
Medigene AG (FSE: MDG1), an innovative company in the field of immuno-oncology, has successfully executed a 2:1 share capital reduction and consolidation. This strategic move was approved during the Annual General Meeting and underscores the company's dedication to enhancing shareholder value.
Overview of the Share Capital Reduction
The share consolidation will decrease the total number of issued shares from 29,475,189 to 14,737,594. As a result, shareholders will now hold one share for every two shares they owned previously. This important step aims to streamline the capital structure and potentially improve the company's market perception.
Effects on Shareholders
Even though the number of shares has significantly decreased, individual shareholders will not see any change in the overall value of their investments. The total capitalization of Medigene remains stable, ensuring that shareholders do not experience any dilution of their ownership percentages due to this consolidation. The adjusted shares will automatically appear in trading and deposit accounts.
Market Operations Following Consolidation
After the consolidation, share trading will shift to the new securities identification number, WKN A40ESG (ISIN: DE000A40ESG2), starting on August 29. This change is expected to enhance liquidity for shareholders and may elevate the perceived market value of the shares.
Accounting Changes
As part of the consolidation process, Medigene will make a significant accounting adjustment. The company's reporting balance will transition from “subscribed capital” to “capital reserves” in its financial statements. This strategic accounting decision aims to increase the market value of Medigene’s shares beyond their nominal value of EUR 1.00.
Addressing Shareholder Questions
For shareholders whose share counts result in non-divisible amounts, Medigene will provide a “partial rights settlement.” This option allows these shareholders to choose whether they want to buy or sell fractional shares. Notifications will be sent from the depositary bank after the reference date, offering guidance on these options.
About Medigene AG
Medigene AG focuses on developing T cell receptor (TCR)-guided therapies aimed at effectively treating cancer. Their innovative End-to-End Platform produces T cell receptors that are sensitive, specific, and safe. This cutting-edge technology is utilized not only in their internal product pipeline but also in potential collaborations.
Recent Developments in Medigene's Pipeline
Medigene is progressing with its leading TCR-T therapy, MDG1015, which is set to become a top treatment option for various solid tumor types. The company employs advanced techniques to create T cells that can navigate the immunosuppressive tumor microenvironment. MDG1015 is expected to file for an Investigational New Drug (IND) in the upcoming quarters, highlighting Medigene's commitment to advancing cancer therapy.
Contact Information
For any inquiries from shareholders, please reach out to:
Pamela Keck
Phone: +49 89 2000 3333 01
Email: investor@medigene.com
Frequently Asked Questions
What is the share capital reduction ratio implemented by Medigene?
The share capital reduction ratio implemented by Medigene is 2:1, meaning shareholders will receive one share for every two shares they previously held.
When will the new shares start trading?
The new shares will start trading under the new securities identification number on August 29.
Will shareholders see a change in the value of their investments?
No, shareholders will not experience a decrease in their investment value due to the consolidation; the total value remains unchanged.
What happens to fractional shares after consolidation?
Shareholders with fractional shares will have the option to participate in a “partial rights settlement” to decide on managing their fractional shares.
How can investors stay updated on Medigene’s progress?
Investors can stay updated on Medigene’s progress by following their official communications, including press releases and updates posted on their website.
